Eutectic mixtures for advanced creatine delivery formulations
Harness the power of eutectic mixtures to enhance creatine delivery. Our approach blends GRAS compounds for stable liquid formulations, offering flexibility and compatibility for various applications. Ideal for pharmaceutical and nutraceutical innovations.
Overview
Our innovative solution leverages eutectic mixtures to create advanced liquid formulations for creatine delivery. By blending creatine with generally recognized as safe (GRAS) compounds, we enable the transition from solid to liquid states, enhancing bioavailability and stability. This approach is pioneering in formulation science, offering significant potential in pharmaceuticals and nutraceuticals by allowing for finely-tuned, stable formulations optimized to meet specific physical and chemical performance criteria.
Technical specifications
Our technology utilizes hydrogen bond donors and acceptors to form eutectic mixtures, which are versatile and can be customized to achieve desired viscosity and conductivity. We have experience working with binary, ternary, and quaternary mixtures, allowing us to tailor formulations to specific requirements. The technology does not require registration as new compounds, streamlining regulatory processes. Our facilities are equipped for both small-scale sample testing and larger scale co-development projects, ensuring seamless collaboration with partners.
Technology readiness level
The technology is currently at TRL 4, having been validated in laboratory settings with a variety of compounds similar to creatine. Our dedicated scale-up laboratory and high-tech facilities support further development and commercialization efforts.
About University of Leicester
The University of Leicester is a comprehensive public research university in the East Midlands with a global outlook and strong industry collaboration. Space Park Leicester anchors a research and technology park where companies co‑locate with academics, access open facilities such as cleanrooms, and secure incubator and grow‑on workspace to accelerate product development. Clinical translation is enabled through integration with University Hospitals of Leicester NHS Trust and the NIHR Leicester Biomedical Research Centre. Research is backed by competitive funding from UK Research and Innovation and its councils, Innovate UK, and the National Institute for Health and Care Research. A dedicated commercialization team supports IP, licensing, spin‑outs, and routes for contract research, consultancy, and Knowledge Transfer Partnerships.
Inquire about this partnering listing
Looking for
Industry applications
delivered to your inbox.